Indivior PLC - Chesterfield, Virginia-headquartered pharmaceutical maker - Reconfirms financial guidance for 2024 ahead of analyst ’teach-in’ event in New York. Indivior also on Thursday is asking shareholders to approve moving its primary listing to New York from London.

Indivior expects net revenue between $1.24 billion and $1.33 billion in 2024, at least 13% higher than $1.09 billion reported for 2023. Adjusted gross margin is seen in the low to mid-80s range. Expects adjusted operating profit between $330 million and $380 million, up at least 23% from $269 million in 2023. Research & development costs are set to increase at least 13% to between $120 million and $130 million from $106 million in 2023.

Current stock price: 1,369.50 pence each, up 3.4% on Thursday afternoon in London

12-month change: down 6.8%

Copyright 2024 Alliance News Ltd. All Rights Reserved.